FMP
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0.439 USD
-0.0091 (-2.07%)
Seeking Alpha
Apr 1, 2024
Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript
Accesswire
Mar 25, 2024
Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024. The Company plans to hold its earnings call, open to the public, at 4:30 pm ET on Monday, April 1st, to discuss the results of ...
Accesswire
Oct 13, 2023
NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced its FY 2022 annual shareholder meeting will be held Wednesday, December 13, 2023, at 10:00 am EST, for shareholders of record as of this coming Monday, October 16th. Those who would like to attend the meeting virtually may do so by going to the website www.virtualshareholdermeeting.com/...
Accesswire
Apr 26, 2022
NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic disorders, today announced will be presenting at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference tomorrow, April 27, 2022.
Pulse2
Aug 19, 2021
The shares of Protagenic Therapeutics Inc (NASDAQ: PTIX) increased by over 10% pre-market. This is why it happened.
Benzinga
Jul 26, 2021
Upon reviewing Protagenic Therapeutics Inc's (NASDAQ: PTIX) Investigational New Drug (IND) application for its lead compound, PT00114, the FDA has currently rejected the Company's IND. The application sought approval to start a Phase 1/2a basket study designed to test PT00114 in healthy volunteers and patients with PTSD, anxiety, and depression.
GlobeNewsWire
Jul 6, 2021
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that it will host a key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction on Tuesday, July 13 at 10:00AM ET.
InvestorPlace
Jun 24, 2021
Penny stocks offer a lot of risk balanced by lots of reward. Here are 7 that could surge in price and which have reasonable catalysts behind them.
Pulse2
Jun 11, 2021
The stock price of Protagenic Therapeutics Inc (NASDAQ: PTIX) increased by over 25% pre-market. These are the details.
PennyStocks
May 26, 2021
Looking for biotech penny stocks for your June watchlist? Here's 4 to watch The post Best Biotech Penny Stocks in June 2021?